Pfizer has named Patrizia Cavazzoni, the former head of the FDA drug review division, to serve as its top doctor.

Critics often refer to such personnel transitions between federal health agencies and major pharmaceutical companies as a “revolving door,” expressing concerns about the agencies’ independence potentially being compromised by corporate interests.